By Tom Whitfield

Sanofi and the pan-Canadian Pharmaceutical Alliance (pCPA) signed a Letter of Intent this week covering Dupixent (dupilumab) across four indications in dermatology and respiratory care, the companies confirmed.

The agreement opens formal price and listing negotiations between pCPA, the body that negotiates drug prices on behalf of Canada's provincial, territorial, and federal public drug plans, and Sanofi, which markets Dupixent with Regeneron Pharmaceuticals.

The four indications under the LOI fall into two therapeutic areas: dermatology and respiratory medicine. The specific conditions, financial terms, and a firm timeline were not disclosed in the announcement. The companies also did not provide direct executive quotes in the initial release.

What the LOI does

A Letter of Intent is the standard first step in pCPA's process. It signals that price and listing discussions are underway and lays the groundwork for a subsequent agreement that would set reimbursement terms across Canada's publicly funded drug programs.

The pCPA, formed in 2010, negotiates jointly with manufacturers to leverage combined public-sector buying power. An LOI does not bind either side to final pricing or coverage decisions, but a completed pCPA agreement is typically a precondition for any province or territory to list a drug on its public formulary at the negotiated price.

Individual provinces and territories then run their own review and listing steps, which can add weeks or months between a pCPA deal and patient access through a public plan. Some provinces list under pCPA terms directly; others layer additional review through bodies such as CADTH, the Canadian Agency for Drugs and Technologies in Health, or provincial health technology assessors like Quebec's INESSS.

Why the dermatology and respiratory scope matters

Dupixent is a subcutaneous monoclonal antibody, and the four indications under the LOI span both dermatology and respiratory care, two of the drug's core therapeutic areas. A coordinated pCPA agreement covering multiple indications at once is less common than single-indication deals and would set a uniform price framework for all four uses.

That structure could simplify formulary management for the participating plans and accelerate uptake in indications that might otherwise face separate, sequential negotiations. It also positions Dupixent across a broader footprint than the typical respiratory-only or dermatology-only deal, reflecting the drug's cross-specialty positioning.

For Sanofi and Regeneron, a unified framework would reduce the administrative load of maintaining multiple parallel negotiations. For payers, a single price across indications eases budget forecasting and supports parity of access between provinces that might otherwise have negotiated separate terms.

What to watch

Sanofi has not yet disclosed the four specific indications covered by the LOI, the negotiating timeline, or whether pricing details will become public before a final agreement. Provincial and territorial listings would follow on their own schedules after any final pCPA deal, and the participating jurisdictions are also yet to be confirmed.

A key signal for Canadian prescribers will be whether the final pCPA agreement lists indications by name and whether any restrictions, such as prior therapy failures or specialist-only prescribing, carry over from current provincial criteria.

Further details — including indication names, agreed pricing, and listing dates — are expected to emerge as the negotiations advance.